Latest Everolimus Stories
NATICK, Mass., May 1, 2014 /PRNewswire/ -- Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has launched the Promus PREMIER(TM) Everolimus-Eluting
- First-of-its-Kind Dissolving Medical Device Being Evaluated in People with Blocked Heart Vessels ABBOTT PARK, Ill., April 10, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced
- Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC - LAUSANNE, Switzerland and LEXINGTON, Mass., April
These and Other Studies Reinforce Global Commitment to the Development of Innovative Therapies to Improve Care for Patients with Cardiovascular Disease NATICK, Mass., April 1, 2014 /PRNewswire/
Newest Bare Metal Stent Technology Features Advanced Architecture and Provides Physicians with Enhanced Treatment Option for Patients NATICK, Mass., March 12, 2014 /PRNewswire/ --
Company Initiates Joint U.S. and Japanese Registration Trial HONG KONG, Feb.
- A political dynamiter.